NanoTemper Technologies and PharmAI Launch Proto, a Free AI Tool to Quickly Determine Which Protein Tagging Strategy Works Best for Molecular Interaction Measurements
MUNICH–(BUSINESS WIRE)–NanoTemper Technologiesin partnership with PharmAI, announced the launch of Proto, a free, AI-powered web application that reveals the best labeling strategy to help scientists more effectively measure molecular interactions, a process needed to discover and develop new drugs. Proto is one of the first commercial applications using the AlphaFold Protein Structure Database which has been made freely available by EMBL-EBI and DeepMindan Alphabet company.
Drug discovery scientists need to detect and measure how well proteins bind to molecules, which requires labeling, usually using a dye. If the wrong labeling strategy is chosen, it leads to time-consuming and costly investigations.
“Proto uses over 700,000 protein structures from AlphaFold or RCSB Protein Database to suggest the appropriate dye for binding measurements,” says Christina Wolf, Data Scientist at NanoTemper. “This makes binding measurements more efficient and reliable, and it gives scientists extra confidence in their results.”
This new tagging prediction is another important step towards optimizing experiments in the biotechnology and pharmaceutical industry using artificial intelligence. “We want to help optimize research into diseases and therapeutics – that’s why we’re making this tool freely available,” says Philipp Baaske, co-CEO of NanoTemper. “There are many rare diseases that are currently not cost-effective for big pharma to study. The possibilities offered by AI-based software could allow small laboratories to enter the field of drug research in the future and make new therapies possible through their work, for the benefit of all,” adds Joachim Haupt, CEO of PharmAI.
Experience Proto for yourself; to visit proto.nanotempertech.com.
About NanoTemper Technologies
Our mission at NanoTemper Technologies is to create biophysical tools for drug discovery and development scientists who need to tackle challenging characterizations. Working with scientists who strive to make a difference in the world excites us. If you’re having trouble with affinity screening, molecular interactions, protein stability, protein expression, or protein quality, let’s talk.
Learn more about www.nanotempertech.com.
PharmAI’s mission is to make early-stage drug development much more efficient by increasing success rates while reducing costs. This is achieved through a revolutionary AI-powered platform for 3D protein structure analysis. This technology will significantly shorten the time to discovery of new therapeutic molecules. PharmAI was founded in 2019 as a spin-off from the Technische Universität Dresden.
Learn more about www.pharm.ai.
Images for Proto can be found in the Photos/Hardware section here: pharm.ai/press.